|
1
|
Nanki T, Nagasaka K, Hayashida K, Saita Y
and Miyasaka N: Chemokines regulate IL-6 and IL-8 production by
fibroblast-like synoviocytes from patients with rheumatoid
arthritis. J Immunol. 167:5381–5385. 2001.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Szekanecz Z, Kim J and Koch AE: Chemokines
and chemokine receptors in rheumatoid arthritis. Semin Immunol.
15:15–21. 2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu
T and Li EK: CXCL 9 and CXCL 10 as sensitive markers of disease
activity in patients with rheumatoid arthritis. J Rheumatol.
37:257–264. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ruschpler P, Lorenz P, Eichler W, Koczan
D, Hänel C, Scholz R, Melzer C, Thiesen HJ and Stiehl P: High CXCR3
expression in synovial mast cells associated with CXCL9 and CXCL10
expression in inflammatory synovial tissues of patients with
rheumatoid arthritis. Arthritis Res Ther. 5:R241–R252.
2003.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Pandya JM, Lundell AC, Andersson K,
Nordstrom I, Theander E and Rudin A: Blood chemokine profile in
untreated early rheumatoid arthritis: CXCL10 as a disease activity
marker. Arthritis Res Ther. 19(20)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Siebert S, Tsoukas A, Robertson J and
McInnes I: Cytokines as therapeutic targets in rheumatoid arthritis
and other inflammatory diseases. Pharmacol Rev. 67:280–309.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Brennan FM and McInnes IB: Evidence that
cytokines play a role in rheumatoid arthritis. J Clin Invest.
118:3537–3545. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Hueber AJ, Asquith DL, McInnes IB and
Miller AM: Embracing novel cytokines in RA-complexity grows as does
opportunity! Best Pract Res Clin. Rheumatol. 24:479–487.
2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mateen S, Zafar A, Moin S, Khan AQ and
Zubair S: Understanding the role of cytokines in the pathogenesis
of rheumatoid arthritis. Clin Chim Acta. 455:161–171.
2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
He R, Yin H, Yuan B, Liu T, Luo L, Huang
P, Dai L and Zeng K: IL-33 improves wound healing through enhanced
M2 macrophage polarization in diabetic mice. Mol Immunol. 90:42–49.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Matsuyama Y, Okazaki H, Tamemoto H, Kimura
H, Kamata Y, Nagatani K, Nagashima T, Hayakawa M, Iwamoto M, Yoshio
T, et al: Increased levels of interleukin 33 in sera and synovial
fluid from patients with active rheumatoid arthritis. J Rheumatol.
37:18–25. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xu D, Jiang HR, Kewin P, Li Y, Mu R,
Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB
and Liew FY: IL-33 exacerbates antigen-induced arthritis by
activating mast cells. Proc Natl Acad Sci USA. 105:10913–10918.
2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rivellese F, Suurmond J, Habets K, Dorjée
AL, Ramamoorthi N, Townsend MJ, de Paulis A, Marone G, Huizinga TW,
Pitzalis C and Toes RE: Ability of interleukin-33- and immune
complex-triggered activation of human mast cells to down-regulate
monocyte-mediated immune responses. Arthritis Rheumatol.
67:2343–2353. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Pushparaj PN, Li D, Komai-Koma M,
Guabiraba R, Alexander J, McSharry C and Xu D: Interleukin-33
exacerbates acute colitis via interleukin-4 in mice. Immunology.
140:70–77. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Palmer G, Talabot-Ayer D, Lamacchia C, Toy
D, Seemayer CA, Viatte S, Finckh A, Smith DE and Gabay C:
Inhibition of interleukin-33 signaling attenuates the severity of
experimental arthritis. Arthritis Rheum. 60:738–749.
2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yuan FL, Li X, Lu WG, Li CW, Xu RS and
Dong J: IL-33: A promising therapeutic target for rheumatoid
arthritis? Expert Opin Ther Targets. 15:529–534. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xu D, Jiang HR, Li Y, Pushparaj PN,
Kurowska-Stolarska M, Leung BP, Mu R, Tay HK, McKenzie AN, McInnes
IB, et al: IL-33 exacerbates autoantibody-induced arthritis. J
Immunol. 184:2620–2626. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Anthony RM, Kobayashi T, Wermeling F and
Ravetch JV: Intravenous gammaglobulin suppresses inflammation
through a novel T(H)2 pathway. Nature. 475:110–113. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mu R, Huang HQ, Li YH, Li C, Ye H and Li
ZG: Elevated serum interleukin 33 is associated with autoantibody
production in patients with rheumatoid arthritis. J Rheumatol.
37:2006–2013. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Talabot-Ayer D, McKee T, Gindre P, Bas S,
Baeten DL, Gabay C and Palmer G: Distinct serum and synovial fluid
interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic
arthritis and osteoarthritis. Joint Bone Spine. 79:32–37.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Aletaha D, Neogi T, Silman AJ, Funovits J,
Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP,
Cohen MD, et al: 2010 Rheumatoid arthritis classification criteria:
An American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Arthritis Rheum. 62:2569–2581.
2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Izawa N, Hirose J, Fujii T, Oka H, Uehara
K, Naito M, Matsumoto T, Tanaka S and Tohma S: The utility of
25-question geriatric locomotive function scale for evaluating
functional ability and disease activity in Japanese rheumatoid
arthritis patients: A cross-sectional study using NinJa database.
Mod Rheumatol. 29:328–334. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wu J, Li Q, Jin L, Qu Y, Liang BB, Zhu XT,
Du HY, Jie LG and Yu QH: Kirenol Inhibits the function and
inflammation of fibroblast-like synoviocytes in rheumatoid
arthritis in vitro and in vivo. Front Immunol.
10(1304)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Biton J, Khaleghparast Athari S, Thiolat
A, Santinon F, Lemeiter D, Hervé R, Delavallée L, Levescot A, Roga
S, Decker P, et al: In vivo expansion of activated Foxp3+
regulatory T cells and establishment of a type 2 immune response
upon IL-33 treatment protect against experimental arthritis. J
Immunol. 197:1708–1719. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Machado CRL, Resende GG, Macedo RBV,
Nascimento VC, Sliva TP, Kakehasi AM and Andrade MVM: AB0028
Fibroblast-like synoviocytes may not be the target of il-33 in the
joint phisiopathology. Ann Rheum Dis. 76 (Suppl 2)(S1056)2017.
|
|
27
|
Lee EJ, So MW, Hong S, Kim YG, Yoo B and
Lee CK: Interleukin-33 acts as a transcriptional repressor and
extracellular cytokine in fibroblast-like synoviocytes in patients
with rheumatoid arthritis. Cytokine. 77:35–43. 2016.PubMed/NCBI View Article : Google Scholar
|
